Key result
This letter discusses the limitations of existing studies on anti-inflammatory interventions for atrial fibrillation prevention, emphasizing the need for well-powered randomized trials.
Answers are grounded in this paper and cite their sources.
This reply emphasizes the need for well-powered randomized trials to determine if modifying inflammation can reduce the clinical burden of atrial fibrillation.
We thank Drs Liu and Li for their comments in response to our article dealing with the concept of inflammation and atrial fibrillation (AF). The authors have highlighted additional papers discussing the issue of statin use and AF prevention, which were not included in our manuscript.1,2 However, these were only published or ‘in press’ subsequent to the final submission of our article. Furthermore, Professor Lip is a co-author on one of these papers. With regards to post hoc AF data from the MIRACL study,3 it is our belief that firm conclusions cannot yet be drawn from the inability of high-dose atorvastatin (80 mg/day) to prevent AF occurrence. The study was underpowered for AF events, reporting a very low AF event rate in either the treatment or control group, with a very short follow-up period of only 16 weeks. The Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF) trial is currently underway.4 This will be a randomized double-blinded intention to treat study aiming to recruit 258 patients with persistent AF scheduled for cardioversion, and will ascertain whether 80 mg/day atorvastatin (vs. placebo) will reduce AF over 1-year's follow-up. The quoted reduction in AF after coronary artery bypass grafting (CABG) with the use of non-steroidal anti-inflammatory drugs, in the study by Cheruku et al.,5 is an intriguing one. NSAIDS may indeed decrease the incidence of post-operative paroxysmal AF, perhaps via mediation of local pericardial irritation, but systemic anti-inflammatory effects cannot be excluded. However, this single small study (100 patients) must be treated with caution, as there were intrinsic biases in the risk factors of age and hypertension between the treatment and control groups. Furthermore, the important confounder of left atrial size was not documented. Finally, the study by Merritt et al.6 (purporting to report the superior efficacy of carvedilol over metoprolol or atenolol in reducing AF burden after CABG) was again a small retrospective observational study. There were only 26 patients in the carvedilol group compared with 89 in the atenolol/metoprolol group with marked differences in ejection fraction between the two groups.6 Furthermore, we believe the proposed superior antioxidant effects of carvedilol may be overstated.7 Clearly, the question of whether AF is indeed linked to inflammation is a question worth pursuing, with the need for well-powered randomized trials, given the enormous clinical burden of AF and the therapeutic potential of modifying the associated inflammation. What remains clear from our systematic review is the clear association between inflammation, although it is uncertain whether the effects of associated comorbidities can be truly divorced from this association. Certainly, statistical methods can never fully adjust for all biological and pathophysiological processes. However, inflammation may ‘drive’ the prothrombotic or hypercoagulable state in AF, contributing to the thrombosis-related complications associated with this arrhythmia. It is indeed useful that many drugs used for treating the comorbidities associated with AF can influence both inflammation and the prothrombotic state.
No takes yet. Share an insight, caveat, or question.
C. J. Boos (2005) conducted a letter in Atrial fibrillation. This letter discusses the limitations of existing studies on anti-inflammatory interventions for atrial fibrillation prevention, emphasizing the need for well-powered randomized trials.
Synapse has enriched 10 related papers. Consider them for comparative context: